Printer Friendly

Gliatech receives allowance of United States patent claiming therapeutic antibodies to properdin.

Gliatech Inc. (Cleveland, OH; 216-831-3200) has received a notice of allowance from the United States Patent and Trademark Office for patent claims covering the use of anti-properdin agents as treatments to inhibit harmful inflammation. Gliatech is developing therapeutic antibodies to properdin as potential treatments for acute inflammatory conditions which result from cardiopulmonary bypass surgery, heart attacks and stroke. These antibodies may also provide new therapies for rheumatoid arthritis and other chronic inflammatory diseases.

"The allowance of the patent claims is a significant step in protecting our intellectual property around anti-properdin agents and their promising utility as therapeutic agents," said Steven L. Basta, President of Gliatech. "The progress in this program has been rapid and the collaboration with Abgenix has been rewarding."

Properdin is a protein of the complement alternative pathway, which is a component of the normal host immune system. When the complement pathway is inappropriately triggered, tissue damage may result. Such is the case with acute damage, for example from stimulation of the complement pathway by cardiopulmonary bypass surgery. In chronic diseases, such as rheumatoid arthritis, the immune system aberrantly recognizes the patient's own tissue and mounts an autoimmune response. Activation of the complement pathway in such a disease is thought to propagate this attack.

Gliatech has developed proprietary monoclonal antibodies to properdin that are potent in vitro and in vivo inhibitors of the complement alternative pathway. By selectively blocking the alternative pathway, the negative consequences of inappropriate complement activation can be attenuated without inhibiting other key elements of the normal host immune defense. Gliatech has demonstrated in preclinical models that anti-properdin antibodies can reduce damage to heart tissue in models of reduced blood flow to heart tissues. In addition, the anti-properdin antibodies effectively block complement activation in models of cardiopulmonary bypass surgery.

Gliatech is collaborating with Abgenix, Inc. (Fremont, CA; 510-608-6500) to develop fully human monoclonal antibodies through Abgenix's XenoMouse technology. The companies have identified candidate antibodies to properdin for use as a therapeutic in cardiovascular and inflammatory diseases.

"We have identified several potent and selective monoclonal antibodies and are in the final stages of selecting a clinical candidate from the Abgenix collaboration," stated Clark E. Tedford, Ph.D., Executive Vice President, Research and Development. "The next phase will be the scale up manufacturing and safety/toxicity testing of the clinical candidate to support the regulatory filings for initiation of human clinical trials."

Gliatech Inc. is engaged in the discovery and development of biosurgery and pharmaceutical products. The biosurgery products include ADCON-L and ADCON-T/N and ADCON Solution, which are proprietary, resorbable, carbohydrate polymer medical devices designed to inhibit scarring and adhesions following surgery. Gliatech's pharmaceutical product candidates include small molecule drugs to modulate the cognitive state of the nervous system and proprietary monoclonal antibodies designed to inhibit inflammation.
COPYRIGHT 2001 Biotech Patent News
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2001 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Comment:Gliatech receives allowance of United States patent claiming therapeutic antibodies to properdin.
Publication:BIOTECH Patent News
Article Type:Brief Article
Geographic Code:1USA
Date:Oct 1, 2001
Previous Article:Biotech Holdings patent rights strengthened by new United States patent.
Next Article:Ventana awarded patent covering automated molecular pathology apparatus.

Related Articles
Abgenix and Gliatech enter Xenomouse technology collaboration.
Cambridge Antibody Technology comments on Griffiths patent.
Cambridge Anitbody Technology gains access to Incyte cDNA clone database.
BioCurex receives patent allowance for cancer detection and treatment.
Cytogen granted summary judgment of non-infringement of prostate cancer patent.
Cambridge Antibody announces therapeutic antibody licence agreement with Micromet.
Immunomedics awarded patent for humanized carcinoembryonic antigen antibody.
Peregrine announces patent grant for angiogenesis therapy.
Biolex announces broad patent covering treatment of humans with plant-made antibodies.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters